HepaRegeniX to Present Interim Phase 1b Data for Darizmetinib (HRX215) in a Late-Breaking Oral Presentation at the European Association for the Study of the Liver (EASL) Congress 2026

AI Briefing

• – HepaRegeniX selects darizmetinib (HRX215) for late-breaking oral presentation at EASL Congress 2026.
• – Company to present interim Phase 1b data for darizmetinib in patients after hepatectomy due to colon carcinoma metastases.
• – HepaRegeniX to present scientific rationale for darizmetinib and MKK4 inhibition at 5th International Symposium on Regenerative Hepatology.